Phase 1 Recruiting

GV-100

Sponsor

Gilva Therapeutics

Trial Name

First-in-Human SAD/MAD

Start Date

2026-06

Est. Completion

2027-03

Participants

80

Location

Undisclosed

NCT ID

NCT07788014

Mechanism

Undisclosed oral drug candidate developed for ADPKD.

Detailed article coming soon. See the trial details above for current information.

Disclaimer: This information is for educational purposes only and is not medical advice. Clinical trial information is based on publicly available data from ClinicalTrials.gov and published research. Consult your nephrologist before making treatment decisions.

Stay Updated on PKD Research

Get notified when new drugs enter clinical trials, trial results are published, or approved treatments change.

No spam. Unsubscribe anytime.